{"name":"HuidaGene Therapeutics Co., Ltd.","slug":"huidagene-therapeutics-co-ltd","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMilAJBVV95cUxNNzg2TG1VWW1CdXdkQUFuUzRVd0JGQ0x0OEMyQ2p6OWh1QjRnXy1fUXQzTFJyRkpWdEVaZ0t6R21qelJjVEpjRzdTMnU1S0M4dVphZ1o1aGhiVEx6ams2QjFVQ1ROSkV0RkwtU1c0SjVDZUJoZ1JLczFveEhXekxHOGtadF9IR193bVhMVFhiSThlNk9TaFl2TVYzcVA1ajFMbjFqbDRmTkJnMXVKUmh0YldiZVh6QkVWSnM3QUpCTmhYdEh3c3RMS2NlOWo4NzNQMkhaVmp6Q0Vmdnp6OUNsT2hONWh4ek5ZZDRIdWFXeDJKbm5kbjlNY05lMnhyTzRGRkRaeXlFZFM4MUtVbmg1M1BKWFc?oc=5","date":"2026-04-01","type":"trial","source":"Barchart.com","summary":"AAV Vectors in Gene Therapy Clinical Trial Pipeline Accelerates as 180+ Pharma Companies Rigorously Develop Drugs for Market Entry | DelveInsight - Barchart.com","headline":"AAV Vectors in Gene Therapy Clinical Trial Pipeline Accelerates as 180+ Pharma Companies Rigorously Develop Drugs for Ma","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMifEFVX3lxTE91UlIwVWZ5aDBlLURuT1d5bDRwZFZWOTRtWS0wb3pHOThuRGVxbEVia3RzSUlVVkdDcmhXalNsUk05TXVpUEtsakdKdjB2WXd5ZHFUTWJ5RklnN2hxSzNEdmdCYlFCUVc3aEJXc1pQb3ROdTJVSUVMWm9qZXM?oc=5","date":"2025-03-19","type":"pipeline","source":"Pharma Voice","summary":"The key factors shaping China’s biopharma boom - Pharma Voice","headline":"The key factors shaping China’s biopharma boom","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiiAFBVV95cUxPYTBCUzJmNGN5WHZ0VFM5aThrNzdDeVhtdDJMRDVXVEtzTGN1M0FyVkVtMEpGWVpTUmJTd3RKN2dBYzM3RDZ0WHpNbUMxN2d3eVpRelR4MXdVRGMySGJzZk9qZ215WkJoS0x1Yzk4dDI0VTVGX21lUDNyYVg4bHd5Q3BoYkpUVVh5?oc=5","date":"2025-03-17","type":"pipeline","source":"statnews.com","summary":"These 12 Chinese companies are poised to transform CRISPR gene-editing - statnews.com","headline":"These 12 Chinese companies are poised to transform CRISPR gene-editing","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMihAJBVV95cUxNNTRiT2M1ZVFMS05LQVFRZnRlRTU2bDRwRGRIMXh2bERfbUZZQlE1aVEwV3FtZ3dEam5rNjVPbDFnUHZrcU5GVTRYNjJwV3NjbmtCV0g0Y1hveWhvcUJNYkp1cGVHV2tkZzdnUmxpNlRnR3ZSMng1aEhwcEJKR0JxeUdQdG1JWjlVdVVHQ1k2bXN2MlN0TDVrTG4ta011ajgtd2plTFZsenhRcVNFYUJYTmI1V1BCZ3ExM1lJaENuamlfS0FQQkN3ZWprQXJRZ2JnMDlrVlN6NWdOWFI1R2VtUzc0Q2c0bXlCNW1CMWFKSGZQSGlOQnl0WHFlU09KdV9KcGR4Vg?oc=5","date":"2024-11-04","type":"regulatory","source":"PR Newswire","summary":"HuidaGene Therapeutics Receives the First-Ever FDA Clearance of CRISPR/Cas13 RNA-Editing HG202 for Macular Degeneration - PR Newswire","headline":"HuidaGene Therapeutics Receives the First-Ever FDA Clearance of CRISPR/Cas13 RNA-Editing HG202 for Macular Degeneration","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMioAJBVV95cUxPVkRMZTFPNWRnTEliZmx2X2haQUE0ZHJ6TWlGM1V4OElCRjVGMVE4VlpSN0NKLW5hd1pZbHR3QWFQbU1NUHAyWldwd0ZaTVpMY1ZBaFlWU3ZZbHpZVkJsRUtEWnB6XzIyTFlPRGdYVmpHakR6RUVWdWxVcnppcm9neEtOaGIwT0lUZnFrWXJ4TmhuVlZlU1pUcEl2X0Z3VERmdW1ydXA1RmR3WkxqZUtwTUpYTkFISU94YjRYSGRCZnNfaUhRV1l3SzhIN29yd1hGblhqa2lVOEFLMXlxeU1FUVo5clhTY1JpMjUzbFpyOFVxMGctczBwZlZNTjJJMjgwSnppaGM1T2pJbjdBckV4ZnRtTTZVVUl1cG1mS1hlX2w?oc=5","date":"2024-10-22","type":"trial","source":"GlobeNewswire","summary":"Gene Therapy Clinical Trial Pipeline Gains Momentum: 180+ - GlobeNewswire","headline":"Gene Therapy Clinical Trial Pipeline Gains Momentum: 180+","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMizgJBVV95cUxNY0F6dWlrZk5DekFxRG15YnljVkV0QkV2N21pTlFkUUJtcWdwSjFpYTNFVHFlVzVBcTVjMTdZUzhfNTNLY3JNOW5LN0dnRWh4ZmZOeUROb2FuNUd2NVFqMXlmQnVlUWk4MzduQ3REbzFlQ0dzdXV0N3JZUHMyQnBJOFU4V2RlRzE3a25ldkc5TnljU0RsYVAwc2wzRVg4S2gwSEoyeUlHWUNoSDhMcVFWYTRPNHBnRDFpdEJOZHFRa3RXVWZoTGYxLWRyYWlCSDFKRTRBTGg1cHdMZ3llVzRvcXF1RmpUbVRpa1NXWmpMWnk5ajNvN0VHdXZCTXFzOTVQZlE3dVlKTVVVSk1RVG9oZ3hfd1JoMUttTG11YncxSXVvVzc0aF8xMTRobHdRVHZKM0NuRFZjbmpHLXEwdVhHMnk3dTdrLWEyMV92Tnp3?oc=5","date":"2024-02-19","type":"trial","source":"GlobeNewswire","summary":"Gene Therapies In Ophthalmology Clinical Trial Pipeline - GlobeNewswire","headline":"Gene Therapies In Ophthalmology Clinical Trial Pipeline","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi0wFBVV95cUxPU2htMHhnUERsMkV2Y0JDTHp6VUw3cFZwV19DenNReG5kV01sZlRmeGFHaUZYYTc2UkpZQUlQTkNUM3NDYWI2dmtKS3NCT0NLQi1iLUFSM3dNcXQ1VVUwQzIydDk1YmI2cGJndlZ3LW16aFJYUjFsQk1xamFqZ1ZJczRQWGxBc3dEZ3R2eTNlWDJjYkdDbDI1N182U1l5VURaWC02LTl5MkNvQlk3N0hsQzQ1RGJ2TUNHRDRMVWVsTXUyWVMyQ2JXZlc1SFAyaE9EQW8w?oc=5","date":"2024-02-14","type":"pipeline","source":"CRISPR Medicine News","summary":"HuidaGene Receives Special Designation for Potentially New CRISPR Therapy for Duchenne Muscular Dystrophy - CRISPR Medicine News","headline":"HuidaGene Receives Special Designation for Potentially New CRISPR Therapy for Duchenne Muscular Dystrophy","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMigwJBVV95cUxPMUpuaGJqT015MWdsR21ibGtubWZZSWdZS3h0cktpczJocEE5WXo0c2ctQ3RDenJicHdYSVpkelM3eWJZN0lyUTctc2pCdFU3cl9YTXRSWXdjRXh4am4yUUlNYzFZWkpOZ0ozT0NGdnhxYmpJQjk5bmx3QjVSVC1UcGE1d242RUN2N0ZfS3hJN2tiMXlVc2JPZXpsRjBxa2x3ZGlWdlZJRjVkNFBDQTJjNlVpUENBa0MzcGdCN08xcWQtQzdlQ2JVd0dsak1MbWNubnlZY3lLS1Vmc19TTHBaRXpxckVUdjZ2TTZwazBYdUFvNE1wZWozakJiRzQ3ZkNiRVFB?oc=5","date":"2023-11-01","type":"trial","source":"PR Newswire","summary":"HUIDAGENE THERAPEUTICS ANNOUNCES FIRST PATIENT DOSED IN MULTINATIONAL PHASE 1/2 TRIAL OF HG004 FOR INHERITED BLINDNESS - PR Newswire","headline":"HUIDAGENE THERAPEUTICS ANNOUNCES FIRST PATIENT DOSED IN MULTINATIONAL PHASE 1/2 TRIAL OF HG004 FOR INHERITED BLINDNESS","sentiment":"neutral"}],"patents":[],"drugCount":0,"phaseCounts":{},"enrichmentLevel":0,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}